The drug major continues to see healthy demand across key markets, with US and Europe businesses performing in line with expectations, said its Vice-Chairman and Managing Director K Nithyananda Reddy

New Delhi: Aurobindo Pharma on Wednesday posted a 4 per cent increase in its consolidated net profit to Rs 848 crore for the second quarter ended September 30, aided by robust sales in the US and Europe markets.

The Hyderabad-based drug major had reported a net profit of Rs 817 crore in the July-September period of the last fiscal.

Its revenue from operations rose to Rs 8,286 crore for the September quarter from Rs 7,796 crore in the year-ago period, Aurobindo Pharma said in a statement.

“Q2 has been another steady quarter for Aurobindo, demonstrating the resilience of our base busine

See Full Page